Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

# Johns Hopkins University School of Medicine

Home » # Johns Hopkins University School of Medicine
Combination locoregional therapy with systemic therapy for intermediate and advanced stage HCC

Combination locoregional therapy with systemic therapy for intermediate and advanced stage HCC

Posted by By Xiaorong JI 2024.02.19
<Hepatology Digest>: How does the combination locoregional therapy with systemic therapy improve the prognosis and survival rates for patients with intermediate and advanced stage HCC, and what are the synergistic effects…
Read More
Current treatment status and challenges for intermediate and advanced stage HCC

Current treatment status and challenges for intermediate and advanced stage HCC

Posted by By Xiaorong JI 2024.02.18
<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?
Read More
Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Posted by By Xiaorong JI 2024.01.31
Read More
Recent Posts
  • 2026 EHA Academic Frontier: Professor Stephen Ansell Deeply Analyzes the Biological Characteristics and Immune Microenvironment Remodeling of Classical Hodgkin Lymphoma
  • EHA 2026 | Interpretation by Professor Todd Knepper: Molecular Surveillance and Clinical Trajectories of Donor-Derived Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation
  • Frontline Perspectives from EHA 2026: Iterations in CAR-T Manufacturing Processes and Innovations in Engineering Platforms for Multiple Myeloma
  • 2026 EHA Academic Feast: Multiple Myeloma Treatment Enters a New Era of Precision Stratification—From Reshaping ASCT Status to Breaking the Deadlock in Ultra-High Risk Strategies
  • EHA Echoes · Voices from China | Prof. Meng Lü: CAR-T vs Antibody-Based Therapy as a Bridge to Transplantation—Defining the Optimal Stratified Approach for R/R B-ALL
Recent Comments
    Archives
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top